1 |
(-)-epicatechin |
Epicatechin |
- |
- |
- |
086 2件: 86, 113 💬 |
2 |
(pyr1)apelin-13 |
- |
- |
- |
- |
086 1件: 86 💬 |
3 |
(s)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid |
- |
- |
- |
- |
086 1件: 86 💬 |
4 |
(s)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium |
- |
- |
- |
- |
086 1件: 86 💬 |
5 |
**comment**- imp inhalation solution identical to ventavis inhalation solution, but imp is in a different volume presentation. please see covering letter. |
- |
- |
- |
- |
086 1件: 86 💬 |
6 |
10-nitro-9(e)-octadec-9-enoic acid |
- |
- |
- |
- |
086 1件: 86 💬 |
7 |
11c-acetate |
Acetate |
- |
- |
- |
013 3件: 13, 86, 88 💬 |
8 |
120 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
9 |
15 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
10 |
150mg cxa-10 |
CXA-10 |
- |
- |
- |
086 1件: 86 💬 |
11 |
171 |
- |
- |
- |
- |
086 1件: 86 💬 |
12 |
2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-n-(methylsulfonyl)actamide |
- |
- |
- |
- |
086 1件: 86 💬 |
13 |
2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl) acetamide |
Acetamide |
- |
- |
- |
086 1件: 86 💬 |
14 |
20 mg sildenafil citrate by mouth |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
15 |
25% mtd sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
16 |
45 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
17 |
4au76 |
- |
- |
- |
- |
086 1件: 86 💬 |
18 |
66215-101 |
- |
- |
- |
- |
086 1件: 86 💬 |
19 |
6r-bh4 |
Sapropterin |
1件: D08505 D08505 💬 |
- |
- |
086 3件: 86, 124, 240 💬 |
20 |
75mg cxa-10 |
CXA-10 |
- |
- |
- |
086 1件: 86 💬 |
21 |
90 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
22 |
: 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-n- |
- |
- |
- |
- |
086 1件: 86 💬 |
23 |
[11c]-gsk2256098 500 mbq |
GSK2256098 |
- |
- |
- |
086 1件: 86 💬 |
24 |
[18f] fes |
- |
- |
- |
- |
086 1件: 86 💬 |
25 |
[18f]fluoro-2-deoxy-2-d-glucose |
D-glucose |
1件: D00009 D00009 💬 |
- |
- |
086 2件: 86, 88 💬 |
26 |
Abi-009, nab-rapamycin, albumin-bound rapamycin |
Sirolimus |
1件: D00753 D00753 💬 |
MTOR 1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
086 1件: 86 💬 |
27 |
Access program - sildenafil citrate, viagra, revatio |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
28 |
Ace-011 |
- |
- |
- |
- |
086 1件: 86 💬 |
29 |
Acetamide |
Acetamide |
- |
- |
- |
086 1件: 86 💬 |
30 |
Acetaminophen |
Acetaminophen |
1件: D00217 D00217 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
011 14件: 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271 💬 |
31 |
Acetate |
Acetate |
- |
- |
- |
001 43件: 1 , 2 , 6 , 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 💬 |
32 |
Act - 064992 |
- |
- |
- |
- |
086 1件: 86 💬 |
33 |
Act-050089 |
- |
- |
- |
- |
086 1件: 86 💬 |
34 |
Act-050089 (ro 61-0612) |
- |
- |
- |
- |
086 1件: 86 💬 |
35 |
Act-064992 |
- |
- |
- |
- |
051 5件: 51, 85, 86, 88, 210 💬 |
36 |
Act-064992d |
- |
- |
- |
- |
086 1件: 86 💬 |
37 |
Act-178418 |
- |
- |
- |
- |
086 1件: 86 💬 |
38 |
Act-293987 |
- |
- |
- |
- |
051 3件: 51, 86, 88 💬 |
39 |
Act-293987 (ns-304) |
- |
- |
- |
- |
086 1件: 86 💬 |
40 |
Act-385781a |
- |
- |
- |
- |
086 1件: 86 💬 |
41 |
Act-385781a (actelion epoprostenol) |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
42 |
Actriia-igg1fc |
- |
- |
- |
- |
086 1件: 86 💬 |
43 |
Adcirca |
- |
- |
- |
- |
086 1件: 86 💬 |
44 |
Adcirca 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
45 |
Adcirca® |
- |
- |
- |
- |
086 1件: 86 💬 |
46 |
Adempas |
- |
- |
- |
- |
051 5件: 51, 86, 88, 225, 299 💬 |
47 |
Adempas (riociguat, bay63-2521) |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 2件: 86, 88 💬 |
48 |
Adempas - 0,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
086 1件: 86 💬 |
49 |
Adempas - 1 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
50 |
Adempas - 1,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
51 |
Adempas - 2 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
52 |
Adempas - 2,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
53 |
Adempas 0.5 mg |
- |
- |
- |
- |
086 2件: 86, 299 💬 |
54 |
Adempas 0.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
55 |
Adempas 1 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
56 |
Adempas 1.0 mg |
- |
- |
- |
- |
086 2件: 86, 299 💬 |
57 |
Adempas 1.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
58 |
Adempas 1.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
59 |
Adempas 2 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
60 |
Adempas 2.0 mg |
- |
- |
- |
- |
086 2件: 86, 299 💬 |
61 |
Adempas 2.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
62 |
Adempas 2.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
63 |
Adempas® |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
64 |
Adempas® 0.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
65 |
Adempas® 1.0 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
66 |
Adempas® 1.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
67 |
Adempas® 2.0 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
68 |
Adempas® 2.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
69 |
Adempas¿ 0.5 mg compressa rivestita con film |
- |
- |
- |
- |
086 1件: 86 💬 |
70 |
Adempas¿ 1.0 |
- |
- |
- |
- |
086 1件: 86 💬 |
71 |
Adempas¿ 1.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
72 |
Adempas¿ 2.0 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
73 |
Adempas¿ 2.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
74 |
Adipose derived mesenchymal stem cells |
- |
- |
- |
- |
086 1件: 86 💬 |
75 |
Aerosolized iloprost |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
76 |
Air001 |
- |
- |
- |
- |
086 1件: 86 💬 |
77 |
Air001 (sodium nitrite inhalation solution) |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
78 |
Air001 inhalation solution |
- |
- |
- |
- |
086 1件: 86 💬 |
79 |
Air001 inhalation solution (expansion arm) |
- |
- |
- |
- |
086 1件: 86 💬 |
80 |
Al |
- |
- |
- |
- |
005 9件: 5 , 6 , 7 , 28, 51, 67, 86, 114, 127 💬 |
81 |
Albuterol |
Salbutamol |
1件: D02147 D02147 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
012 8件: 12, 13, 86, 89, 113, 231, 256, 299 💬 |
82 |
Albuterol first |
Salbutamol |
1件: D02147 D02147 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
83 |
Albuterol. |
Salbutamol |
1件: D02147 D02147 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
84 |
Allogeneic human cardiosphere-derived stem cells |
- |
- |
- |
- |
086 1件: 86 💬 |
85 |
Ambrisentan |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 7件: 51, 84, 85, 86, 88, 210, 211 💬 |
86 |
Ambrisentan - high dose |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
87 |
Ambrisentan - low dose |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
88 |
Ambrisentan 5 mg film-coated tablets |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
89 |
Ambrisentan 5mg film-coated tablets [marketed product] |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
90 |
Ambrisentan plus spironolactone |
Ambrisentan |
2件: D00443 D00443, D07077 D07077 💬 |
EDNRA 2件: EDNRA, NR3C2 💬 |
Aldosterone-regulated sodium reabsorption 8件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
91 |
Ambrisentan tablet |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
92 |
Ammonia |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
006 4件: 6 , 17, 86, 88 💬 |
93 |
Amn107 |
- |
- |
- |
- |
034 2件: 34, 86 💬 |
94 |
Anakinra |
Anakinra |
1件: D02934 D02934 💬 |
IL1R1 2件: IL1R1, IL1R2 💬 |
Amoebiasis 15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
002 17件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 💬 |
95 |
Anastrozole |
Anastrozole |
1件: D00960 D00960 💬 |
CYP19A1 1件: CYP19A1 💬 |
Metabolic pathways 3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
078 3件: 78, 86, 193 💬 |
96 |
Angiotensin |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 7件: 17, 19, 46, 66, 86, 222, 224 💬 |
97 |
Apabetalone |
Apabetalone |
1件: D11131 D11131 💬 |
- |
- |
086 1件: 86 💬 |
98 |
Apd811 |
- |
- |
- |
- |
086 1件: 86 💬 |
99 |
Apelin |
- |
- |
- |
- |
086 1件: 86 💬 |
100 |
Apn01 |
Recombinant Human Angiotensin-Converting Enzyme 2 |
- |
- |
- |
086 1件: 86 💬 |
101 |
Ar392830 |
- |
- |
- |
- |
086 1件: 86 💬 |
102 |
Aspirin |
Acetylsalicylic acid |
1件: D00109 D00109 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
013 11件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 210, 231 💬 |
103 |
Assigned pulmonary hypertension medication |
- |
- |
- |
- |
086 1件: 86 💬 |
104 |
Autologous epcs transfected |
- |
- |
- |
- |
086 1件: 86 💬 |
105 |
Autologous epcs transfected with human enos |
- |
- |
- |
- |
086 1件: 86 💬 |
106 |
Aviptadil |
Aviptadil |
- |
- |
- |
049 4件: 49, 51, 85, 86 💬 |
107 |
Azd4831 |
- |
- |
- |
- |
086 1件: 86 💬 |
108 |
Bardoxolone |
Bardoxolone |
1件: D09584 D09584 💬 |
- |
- |
066 7件: 66, 67, 84, 85, 86, 218, 222 💬 |
109 |
Bardoxolone methyl |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
066 7件: 66, 67, 84, 85, 86, 218, 222 💬 |
110 |
Bardoxolone methyl capsules |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
066 4件: 66, 67, 86, 222 💬 |
111 |
Bardoxolone methyl, cddo-me, cddo-methyl ester, nsc 713200, chemical name: oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
086 1件: 86 💬 |
112 |
Bay 63-2521 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
113 |
Bay 63-2521 0.06 % |
- |
- |
- |
- |
086 1件: 86 💬 |
114 |
Bay 63-2521 0.3 % |
- |
- |
- |
- |
086 1件: 86 💬 |
115 |
Bay 63-2521 coated tablets 0.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
116 |
Bay 63-2521 coated tablets 1 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
117 |
Bay 63-2521 coated tablets 1.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
118 |
Bay 63-2521 coated tablets 2 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
119 |
Bay 63-2521 coated tablets 2.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
120 |
Bay 63-2521 ir tablets 0.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
121 |
Bay 63-2521 ir tablets 1 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
122 |
Bay 63-2521 ir tablets 1.0 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
123 |
Bay 63-2521 ir tablets 1.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
124 |
Bay 63-2521 ir tablets 2.0 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
125 |
Bay 63-2521 ir tablets 2.5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
126 |
Bay 63-2521 tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
127 |
Bay 63-2521 tablets 0.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
128 |
Bay 63-2521 tablets 1 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
129 |
Bay 63-2521 tablets 1.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
130 |
Bay 63-2521 tablets 2 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
131 |
Bay 63-2521 tablets 2.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
132 |
Bay q 6256 |
- |
- |
- |
- |
086 1件: 86 💬 |
133 |
Bay1237592 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
134 |
Bay63-2521 |
- |
- |
- |
- |
051 3件: 51, 86, 299 💬 |
135 |
Beetroot juice |
- |
- |
- |
- |
086 1件: 86 💬 |
136 |
Benzbromaron |
- |
- |
- |
- |
086 1件: 86 💬 |
137 |
Benzbromaron al |
- |
- |
- |
- |
086 1件: 86 💬 |
138 |
Benzbromarone |
Benzbromarone |
1件: D01056 D01056 💬 |
- |
- |
086 1件: 86 💬 |
139 |
Beraprost |
Beraprost |
1件: D02720 D02720 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
140 |
Beraprost sodium |
Beraprost |
1件: D02720 D02720 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
141 |
Beraprost sodium 314d modified release tablets |
Beraprost |
1件: D02720 D02720 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
142 |
Beraprost sodium modified release |
Beraprost |
1件: D02720 D02720 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
143 |
Bevacizumab |
Bevacizumab |
1件: D06409 D06409 💬 |
VEGFA 1件: VEGFA 💬 |
AGE-RAGE signaling pathway in diabetic complications 22件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
013 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬 |
144 |
Bh4 |
- |
- |
- |
- |
051 5件: 51, 86, 124, 240, 299 💬 |
145 |
Bia |
BIA |
- |
- |
- |
006 2件: 6 , 86 💬 |
146 |
Bia 5-1058 |
BIA |
- |
- |
- |
086 1件: 86 💬 |
147 |
Bia-5-1058 |
BIA |
- |
- |
- |
086 1件: 86 💬 |
148 |
Biological dmards |
- |
- |
- |
- |
086 1件: 86 💬 |
149 |
Bisoprolol |
Bisoprolol |
2件: D00634 D00634, D02342 D02342 💬 |
ADRB1 1件: ADRB1 💬 |
Adrenergic signaling in cardiomyocytes 10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
067 3件: 67, 86, 113 💬 |
150 |
Blood test |
- |
- |
- |
- |
036 5件: 36, 86, 113, 162, 299 💬 |
151 |
Bosentan |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬 |
152 |
Bosentan administration |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
153 |
Bosentan and sildenafil |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
154 |
Bosentan monohidrato |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
155 |
Bosentan monohydrat |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
156 |
Bosentan monohydrate |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 4件: 51, 84, 86, 88 💬 |
157 |
Bosentan, ambrisentan |
Ambrisentan |
3件: D01227 D01227, D07077 D07077, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
158 |
Bps-314d-mr |
- |
- |
- |
- |
086 1件: 86 💬 |
159 |
Bps-mr |
- |
- |
- |
- |
086 1件: 86 💬 |
160 |
Bromure d'ipratropium |
Ipratropium |
1件: D02212 D02212 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
086 1件: 86 💬 |
161 |
Bsf 208075 |
- |
- |
- |
- |
086 1件: 86 💬 |
162 |
Bsf 208075 or lu 208075 |
- |
- |
- |
- |
086 1件: 86 💬 |
163 |
C07ab07 |
- |
- |
- |
- |
086 1件: 86 💬 |
164 |
C225 |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
165 |
Capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 5件: 2 , 6 , 19, 86, 226 💬 |
166 |
Captopril |
Captopril |
1件: D00251 D00251 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
017 2件: 17, 86 💬 |
167 |
Carbon |
Activated charcoal |
1件: D03251 D03251 💬 |
- |
- |
006 9件: 6 , 46, 50, 51, 85, 86, 96, 97, 298 💬 |
168 |
Carbon monoxide |
Activated charcoal |
2件: D03251 D03251, D09706 D09706 💬 |
- |
- |
085 3件: 85, 86, 298 💬 |
169 |
Carvedilol |
Carvedilol |
2件: D00255 D00255, D03415 D03415 💬 |
ADRA1A 5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 |
AMPK signaling pathway 12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6 , 57, 86, 113, 210 💬 |
170 |
Cetuximab |
Cetuximab |
1件: D03455 D03455 💬 |
EGFR 1件: EGFR 💬 |
Adherens junction 46件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
034 5件: 34, 51, 86, 89, 331 💬 |
171 |
Chlorhexidine |
Chlorhexidine |
4件: D00858 D00858, D01345 D01345, D03463 D03463, D07668 D07668 💬 |
- |
- |
086 2件: 86, 299 💬 |
172 |
Cialis |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
173 |
Cialis 10 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
174 |
Cialis 2.5 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
175 |
Cialis 20 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
176 |
Cialis 20 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
177 |
Cialis 5 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
178 |
Cicletanine |
Cicletanine |
1件: D03487 D03487 💬 |
- |
- |
086 1件: 86 💬 |
179 |
Cicletanine hydrochloride |
Cicletanine |
1件: D03487 D03487 💬 |
- |
- |
086 1件: 86 💬 |
180 |
Citrulline |
Citrulline |
1件: D07706 D07706 💬 |
- |
- |
086 2件: 86, 113 💬 |
181 |
Cjnj-68150420-zzz-g001 (act- 064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
182 |
Cjnj-68150420-zzz-g001 (act-064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
183 |
Cjnj-68150420-zzz-g001(act-064992d) |
- |
- |
- |
- |
086 1件: 86 💬 |
184 |
Clopidogrel |
Clopidogrel |
4件: D00769 D00769, D07729 D07729, D10823 D10823, D10824 D10824 💬 |
P2RY12 1件: P2RY12 💬 |
Platelet activation 1件: Platelet activation |
049 2件: 49, 86 💬 |
185 |
Coenzyme q-10 |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
186 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
187 |
Coenzyme q-10 in pulmonary hypertension subjects |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
188 |
Combination product: device: axially oscillating sphere dry powder inhaler (aos dpi) |
- |
- |
- |
- |
086 1件: 86 💬 |
189 |
Combination product: implantable system for remodulin (treprostinil) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
190 |
Combination product: treprostinil via implanted pump |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
191 |
Commercial ventavis® (iloprost) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
192 |
Conivaptan |
Conivaptan |
2件: D01236 D01236, D07748 D07748 💬 |
AVPR1A 2件: AVPR1A, AVPR2 💬 |
Calcium signaling pathway 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption |
086 1件: 86 💬 |
193 |
Conventional drug therapy(expectorant,bronchodilator) |
- |
- |
- |
- |
086 1件: 86 💬 |
194 |
Cosmofer |
- |
- |
- |
- |
086 3件: 86, 96, 97 💬 |
195 |
Current marketed flolan (epoprostenol sodium) |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
196 |
Cxa-10 |
CXA-10 |
- |
- |
- |
086 2件: 86, 222 💬 |
197 |
D-glucose |
D-glucose |
1件: D00009 D00009 💬 |
- |
- |
049 3件: 49, 86, 88 💬 |
198 |
Device: breelib nebulizer |
- |
- |
- |
- |
086 1件: 86 💬 |
199 |
Device: crono five ambulatory pump |
- |
- |
- |
- |
086 1件: 86 💬 |
200 |
Device: endopat measurement |
- |
- |
- |
- |
086 1件: 86 💬 |
201 |
Device: generic dry powder inhaler |
- |
- |
- |
- |
086 1件: 86 💬 |
202 |
Device: i-neb aad system |
- |
- |
- |
- |
086 1件: 86 💬 |
203 |
Device: l606 inhalation system |
- |
- |
- |
- |
086 1件: 86 💬 |
204 |
Device: mhealth intervention |
- |
- |
- |
- |
086 1件: 86 💬 |
205 |
Device: usual care |
- |
- |
- |
- |
086 1件: 86 💬 |
206 |
Dhea |
Prasterone |
1件: D08409 D08409 💬 |
AR 3件: AR, ESR1, ESR2 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
049 3件: 49, 86, 96 💬 |
207 |
Dhea tablet |
Prasterone |
1件: D08409 D08409 💬 |
AR 3件: AR, ESR1, ESR2 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
086 1件: 86 💬 |
208 |
Diagnostic test: cardiac mri (gadolinium enhanced) |
Gadolinium |
- |
- |
- |
086 1件: 86 💬 |
209 |
Diagnostic test: cmri |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
210 |
Diagnostic test: endogenous thrombin potential |
Thrombin |
1件: D00090 D00090 💬 |
- |
- |
086 2件: 86, 88 💬 |
211 |
Diagnostic test: light transmission aggregometry |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
212 |
Diagnostic test: pet-ct imaging with [89zr]-bevacizumab |
Bevacizumab |
1件: D06409 D06409 💬 |
VEGFA 1件: VEGFA 💬 |
AGE-RAGE signaling pathway in diabetic complications 22件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
086 1件: 86 💬 |
213 |
Diagnostic test: platelet function analyzer-100 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
214 |
Diagnostic test: rotational thromboelastometry |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
215 |
Dichloroacetate |
Dichloroacetic acid |
- |
- |
- |
086 1件: 86 💬 |
216 |
Dichloroacetate sodium |
Dichloroacetic acid |
- |
- |
- |
086 1件: 86 💬 |
217 |
Dietanolamina de treprostinilo |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
218 |
Diltiazem |
Diltiazem |
3件: D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 3件: 51, 58, 86 💬 |
219 |
Diltiazem hydrochloride |
Diltiazem |
3件: D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
220 |
Dimethyl fumarate |
Dimethyl fumarate |
1件: D03846 D03846 💬 |
KEAP1 1件: KEAP1 💬 |
Fluid shear stress and atherosclerosis 4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
013 4件: 13, 51, 86, 296 💬 |
221 |
Dimethyl fumarate (dmf) |
Dimethyl fumarate |
1件: D03846 D03846 💬 |
KEAP1 1件: KEAP1 💬 |
Fluid shear stress and atherosclerosis 4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
013 3件: 13, 51, 86 💬 |
222 |
Diphenhydramine |
Diphenhydramine |
6件: D00300 D00300, D00669 D00669, D02419 D02419, D03285 D03285, D03360 D03360, D03854 D03854 💬 |
HRH1 1件: HRH1 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
011 8件: 11, 49, 51, 70, 86, 96, 222, 256 💬 |
223 |
Duo-therapy with sildenafil + bosentan |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
224 |
Efi/act-385781a |
- |
- |
- |
- |
086 1件: 86 💬 |
225 |
Elafin |
Elafin |
- |
- |
- |
086 1件: 86 💬 |
226 |
Endothelin receptor antagonist therapy |
- |
- |
- |
- |
086 1件: 86 💬 |
227 |
Endothelin-3 |
- |
- |
- |
- |
086 1件: 86 💬 |
228 |
Enos transfected epcs will be delivered via a pa line |
- |
- |
- |
- |
086 1件: 86 💬 |
229 |
Epicatechin |
Epicatechin |
- |
- |
- |
086 2件: 86, 113 💬 |
230 |
Epoprostenol |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
231 |
Epoprostenol for injection |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
232 |
Epoprostenol sodico |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
233 |
Epoprostenol sodium |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
234 |
Epoprostenol-actelion |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
235 |
Epoprostenolo per iniezione |
- |
- |
- |
- |
086 1件: 86 💬 |
236 |
Equal |
- |
- |
- |
- |
006 5件: 6 , 13, 67, 86, 230 💬 |
237 |
Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan) |
Bosentan |
6件: D01227 D01227, D02008 D02008, D02229 D02229, D07538 D07538, D08514 D08514, D10135 D10135 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
238 |
Era as specific pah treatment |
- |
- |
- |
- |
086 1件: 86 💬 |
239 |
Erbitux |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
240 |
Esomeprazole |
Esomeprazole |
4件: D01984 D01984, D04056 D04056, D07917 D07917, D09339 D09339 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
013 6件: 13, 46, 86, 98, 298, 299 💬 |
241 |
Esr-specific pet scan |
- |
- |
- |
- |
086 1件: 86 💬 |
242 |
Esuberaprost |
- |
- |
- |
- |
086 1件: 86 💬 |
243 |
Eutonic treprostinil solution |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
244 |
Famotidine |
Famotidine |
1件: D00318 D00318 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
006 4件: 6 , 46, 86, 98 💬 |
245 |
Famotidine 20 mg |
Famotidine |
1件: D00318 D00318 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
086 1件: 86 💬 |
246 |
Fdc macitentan/tadalafil |
Macitentan |
2件: D02008 D02008, D10135 D10135 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
247 |
Ferinject |
- |
- |
- |
- |
086 2件: 86, 299 💬 |
248 |
Ferinject or cosmofer |
- |
- |
- |
- |
086 1件: 86 💬 |
249 |
Ferric carboxymaltose |
Ferric carboxymaltose |
1件: D08920 D08920 💬 |
- |
- |
086 4件: 86, 96, 97, 299 💬 |
250 |
Ferricarboxymaltose |
- |
- |
- |
- |
086 1件: 86 💬 |
251 |
Fk506 level 2-3 ng/ml |
- |
- |
- |
- |
086 1件: 86 💬 |
252 |
Fk506 level 3-5 ng/ml |
- |
- |
- |
- |
086 1件: 86 💬 |
253 |
Fk506 level < 2 ng/ml |
- |
- |
- |
- |
086 1件: 86 💬 |
254 |
Flolan |
- |
- |
- |
- |
086 1件: 86 💬 |
255 |
Flolan injection with currently marketed diluent |
- |
- |
- |
- |
086 1件: 86 💬 |
256 |
Flolan injection with reformulated diluent |
- |
- |
- |
- |
086 1件: 86 💬 |
257 |
Flolan tm and glycine diluent |
Glycine |
1件: D00011 D00011 💬 |
- |
- |
086 1件: 86 💬 |
258 |
Flolan® |
- |
- |
- |
- |
086 1件: 86 💬 |
259 |
Flolan™ and glycine diluent |
Glycine |
1件: D00011 D00011 💬 |
- |
- |
086 1件: 86 💬 |
260 |
Fluoxetine |
Fluoxetine |
2件: D00326 D00326, D00823 D00823 💬 |
SLC6A4 1件: SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
013 4件: 13, 17, 78, 86 💬 |
261 |
Fulvestrant |
Fulvestrant |
1件: D01161 D01161 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
086 1件: 86 💬 |
262 |
G04be03 |
- |
- |
- |
- |
086 1件: 86 💬 |
263 |
G04be03- sildenafil - sildenafil (citrato) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
264 |
Gadolinium |
Gadolinium |
- |
- |
- |
013 6件: 13, 34, 46, 58, 65, 86 💬 |
265 |
Gb002 |
- |
- |
- |
- |
086 1件: 86 💬 |
266 |
Gb002 capsules |
- |
- |
- |
- |
086 1件: 86 💬 |
267 |
Glivec |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
268 |
Glivec 100 mg comprimidos recubiertos con película |
- |
- |
- |
- |
034 2件: 34, 86 💬 |
269 |
Glivec 100 mg filmtabletten |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
270 |
Glivec 100 mg hartkapsel |
- |
- |
- |
- |
086 1件: 86 💬 |
271 |
Glivec® |
- |
- |
- |
- |
086 1件: 86 💬 |
272 |
Glivec® 100 mg filmtabletten |
- |
- |
- |
- |
086 1件: 86 💬 |
273 |
Glucose |
Dextrose, unspecified form |
- |
- |
- |
002 15件: 2 , 6 , 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
274 |
Glycine |
Glycine |
1件: D00011 D00011 💬 |
- |
- |
035 5件: 35, 60, 86, 226, 299 💬 |
275 |
Gma301 injection |
- |
- |
- |
- |
086 1件: 86 💬 |
276 |
Gold |
Gold |
- |
- |
- |
002 38件: 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
277 |
Gradient |
- |
- |
- |
- |
058 4件: 58, 86, 149, 215 💬 |
278 |
Gs-4997 18 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
279 |
Gs-4997 2 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
280 |
Gs-4997 6 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
281 |
Gsk1325760 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
282 |
Gsk1325760a |
- |
- |
- |
- |
086 1件: 86 💬 |
283 |
Gsk2256098 |
GSK2256098 |
- |
- |
- |
086 1件: 86 💬 |
284 |
Gsk2586881 |
- |
- |
- |
- |
086 1件: 86 💬 |
285 |
Hgp1206 |
- |
- |
- |
- |
086 1件: 86 💬 |
286 |
Hydroxyurea |
Hydroxyurea |
1件: D00341 D00341 💬 |
RRM2 1件: RRM2 💬 |
Drug metabolism - other enzymes 6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
003 8件: 3 , 13, 19, 20, 65, 85, 86, 284 💬 |
287 |
Hypotonictreprostinil solution |
- |
- |
- |
- |
086 1件: 86 💬 |
288 |
I.v. selexipag |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
289 |
Ifetroban |
Ifetroban |
1件: D04500 D04500 💬 |
TBXA2R 1件: TBXA2R 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
051 3件: 51, 86, 113 💬 |
290 |
Ilomedin 20 |
- |
- |
- |
- |
086 1件: 86 💬 |
291 |
Ilomedin 20 [20 µg / ml] |
- |
- |
- |
- |
086 1件: 86 💬 |
292 |
Iloprost |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 4件: 51, 84, 85, 86 💬 |
293 |
Iloprost (5 µg) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
294 |
Iloprost (ventavis bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
295 |
Iloprost (ventavis inhaled, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
296 |
Iloprost (ventavis, bayq 6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
297 |
Iloprost (ventavis, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
298 |
Iloprost (ventavis®) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
299 |
Iloprost inhalation solution (ventavis) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
085 2件: 85, 86 💬 |
300 |
Iloprost pd-15 |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
301 |
Iloprost pd-6 |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
302 |
Iloprost,(ventavis, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
303 |
Imatinib |
Imatinib |
2件: D01441 D01441, D08066 D08066 💬 |
ABL1 3件: ABL1, KIT, PDGFRA 💬 |
Acute myeloid leukemia 31件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
013 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬 |
304 |
Imatinib mesilate |
Imatinib |
2件: D01441 D01441, D08066 D08066 💬 |
ABL1 3件: ABL1, KIT, PDGFRA 💬 |
Acute myeloid leukemia 31件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
013 3件: 13, 86, 88 💬 |
305 |
Imatinib mesylate |
Imatinib |
2件: D01441 D01441, D08066 D08066 💬 |
ABL1 3件: ABL1, KIT, PDGFRA 💬 |
Acute myeloid leukemia 31件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
013 5件: 13, 28, 34, 51, 86 💬 |
306 |
Inhaled dry powder treprostinil (liq861) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
307 |
Inhaled iloprost (5 µg) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
308 |
Inhaled iloprost (ventavis, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
309 |
Inhaled nitric oxide |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 2件: 85, 86 💬 |
310 |
Inhaled nitric oxide & inopulse delivery |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
311 |
Inhaled nitric oxide 75 mcg/kg ibw/hr |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 2件: 85, 86 💬 |
312 |
Inhaled no with pulsed delivery |
- |
- |
- |
- |
086 1件: 86 💬 |
313 |
Inhaled prostacyclin |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
314 |
Inhaled treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
084 2件: 84, 86 💬 |
315 |
Ino |
- |
- |
- |
- |
085 2件: 85, 86 💬 |
316 |
Intravenous administration of ferric carboxymaltose |
Ferric carboxymaltose |
1件: D08920 D08920 💬 |
- |
- |
086 1件: 86 💬 |
317 |
Intravenous treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
318 |
Intravenous/subcutaneous treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
319 |
Ipratropium |
Ipratropium |
1件: D02212 D02212 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 86 💬 |
320 |
Iron supplement |
- |
- |
- |
- |
086 1件: 86 💬 |
321 |
Jnj-67896049 |
- |
- |
- |
- |
086 1件: 86 💬 |
322 |
Jnj-67896049 (act-293987) |
- |
- |
- |
- |
086 1件: 86 💬 |
323 |
Jnj-67896062 / act-064992 |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
324 |
Jtt-251 |
- |
- |
- |
- |
086 1件: 86 💬 |
325 |
Kar5585 capsules |
- |
- |
- |
- |
086 1件: 86 💬 |
326 |
L-citrulline malate |
Citrulline |
1件: D07706 D07706 💬 |
- |
- |
086 1件: 86 💬 |
327 |
L606 (liposomal treprostinil) inhalation solution 51ug |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
328 |
Levitra |
- |
- |
- |
- |
013 2件: 13, 86 💬 |
329 |
Lidocaine |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 10件: 6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 |
330 |
Liq861 100 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
331 |
Liq861 106 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
332 |
Liq861 25 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
333 |
Liq861 26.5 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
334 |
Liq861 50 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
335 |
Liq861 53 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
336 |
Liq861 75 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
337 |
Liq861 79.5 µg |
- |
- |
- |
- |
086 1件: 86 💬 |
338 |
Liq861 inhaled treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
339 |
Lisuride |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 2件: 6 , 86 💬 |
340 |
Lloprost(ventavis,bayq6252, 10 µg/ml) |
- |
- |
- |
- |
086 1件: 86 💬 |
341 |
Lloprost(ventavis,bayq6252, 20 µg/ml) |
- |
- |
- |
- |
086 1件: 86 💬 |
342 |
Ly450190 |
- |
- |
- |
- |
086 1件: 86 💬 |
343 |
Macitentan |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 5件: 51, 85, 86, 88, 210 💬 |
344 |
Macitentan (act-064992) |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
345 |
Macitentan 10 mg |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 3件: 51, 86, 88 💬 |
346 |
Macitentan 10 mg tablet, once daily. |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
347 |
Macitentan 37.5 mg |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
348 |
Macitentan 75 mg |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
349 |
Macitentan group |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
350 |
Macitentan tablets |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 2件: 86, 88 💬 |
351 |
Md-711 |
- |
- |
- |
- |
086 1件: 86 💬 |
352 |
Medical air |
Medical air |
- |
- |
- |
085 3件: 85, 86, 193 💬 |
353 |
Metformin |
Metformin |
2件: D00944 D00944, D04966 D04966 💬 |
PRKAA1 2件: PRKAA1, PRKAA2 💬 |
AMPK signaling pathway 19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
002 21件: 2 , 6 , 13, 46, 49, 60, 67, 75, 77, 81, 86, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 💬 |
354 |
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo |
- |
- |
- |
- |
086 1件: 86 💬 |
355 |
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
356 |
Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
357 |
Methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
358 |
Mk-5475 |
- |
- |
- |
- |
086 1件: 86 💬 |
359 |
Mk-8892 |
- |
- |
- |
- |
086 1件: 86 💬 |
360 |
Monitor |
Methamidophos |
- |
- |
- |
002 18件: 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
361 |
Mono-therapy with sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
362 |
Morphine |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
036 5件: 36, 46, 70, 85, 86 💬 |
363 |
Morphine sulfate |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 3件: 46, 85, 86 💬 |
364 |
Moxifloxacin |
Moxifloxacin |
2件: D00874 D00874, D08237 D08237 💬 |
- |
- |
002 8件: 2 , 6 , 46, 49, 85, 86, 240, 299 💬 |
365 |
Moxifloxacin 400 mg |
Moxifloxacin |
2件: D00874 D00874, D08237 D08237 💬 |
- |
- |
086 1件: 86 💬 |
366 |
Multihance |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
367 |
Nebulized combination ipratropium bromide with salbutamol |
Ipratropium |
2件: D02147 D02147, D02212 D02212 💬 |
ADRB2 6件: ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes 17件: Adrenergic signaling in cardiomyocytes, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
368 |
Nebulized ipratropium bromide |
Ipratropium |
1件: D02212 D02212 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
086 1件: 86 💬 |
369 |
New thermo stable formulation of epoprostenol sodium |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
370 |
Nicardipine |
Nicardipine |
2件: D00617 D00617, D08270 D08270 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
070 2件: 70, 86 💬 |
371 |
Nilotinib |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 5件: 6 , 8 , 34, 51, 86 💬 |
372 |
Nilotinib 50 mg |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
086 1件: 86 💬 |
373 |
Nitric oxide |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
046 8件: 46, 85, 86, 98, 210, 251, 294, 299 💬 |
374 |
Nitric oxide for inhalation |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 2件: 86, 299 💬 |
375 |
Nitric oxide generated by the geno nitrosyl delivery system |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
376 |
Nitric oxide plus oxygen |
Nitric Oxide |
2件: D00003 D00003, D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
377 |
Nitrite |
Nitrite |
- |
- |
- |
086 2件: 86, 299 💬 |
378 |
Nitrosyl |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
379 |
Non-biologic dmards |
- |
- |
- |
- |
046 2件: 46, 86 💬 |
380 |
Ns-304 |
- |
- |
- |
- |
070 3件: 70, 86, 88 💬 |
381 |
Null |
- |
- |
- |
- |
006 16件: 6 , 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 💬 |
382 |
Nx1011 |
- |
- |
- |
- |
086 1件: 86 💬 |
383 |
Observational study with patients treated with tracleer, ventavis, veletri, opsumit and/or uptravi |
- |
- |
- |
- |
086 1件: 86 💬 |
384 |
Olaparib |
Olaparib |
1件: D09730 D09730 💬 |
PARP1 2件: PARP1, PARP2 💬 |
Apoptosis 5件: Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis |
086 2件: 86, 285 💬 |
385 |
Opsumit |
- |
- |
- |
- |
086 3件: 86, 88, 210 💬 |
386 |
Opsumit (macitentan) |
Macitentan |
1件: D10135 D10135 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
387 |
Opsumit® |
- |
- |
- |
- |
086 3件: 86, 88, 210 💬 |
388 |
Oral anticoagulant treatment |
- |
- |
- |
- |
086 1件: 86 💬 |
389 |
Oral era |
- |
- |
- |
- |
086 1件: 86 💬 |
390 |
Oral ifetroban |
Ifetroban |
1件: D04500 D04500 💬 |
TBXA2R 1件: TBXA2R 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
051 2件: 51, 86 💬 |
391 |
Oral pde5 inhibitors |
- |
- |
- |
- |
086 1件: 86 💬 |
392 |
Oral selexipag (uptravi) |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
393 |
Oral sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
394 |
Oral treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 2件: 51, 86 💬 |
395 |
Oral treprostinil (ut-15c) sustained release tablets |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
396 |
Other: iloprost (ventavis inhaled, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
397 |
Other: noninvasive actigraphy monitor |
Methamidophos |
- |
- |
- |
086 1件: 86 💬 |
398 |
Other: oxygen supplementation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 1件: 86 💬 |
399 |
Other: standard-of-care |
- |
- |
- |
- |
086 1件: 86 💬 |
400 |
Other: standardized meals |
- |
- |
- |
- |
086 1件: 86 💬 |
401 |
Other: subacute hypoxic exposures |
- |
- |
- |
- |
086 1件: 86 💬 |
402 |
Oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 18件: 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
403 |
Oxygen supplementation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 1件: 86 💬 |
404 |
Oxygen, liquid |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 2件: 86, 88 💬 |
405 |
Pah |
- |
- |
- |
- |
049 3件: 49, 53, 86 💬 |
406 |
Pah medication |
- |
- |
- |
- |
086 1件: 86 💬 |
407 |
Parenteral remodulin (treprostinil) injection |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
408 |
Pb1046 |
- |
- |
- |
- |
086 1件: 86 💬 |
409 |
Pb1046 subcutaneous injection |
- |
- |
- |
- |
086 1件: 86 💬 |
410 |
Pb1046, vip-elp1-120, vasomera |
- |
- |
- |
- |
086 1件: 86 💬 |
411 |
Pemziviptadil (pb1046) |
- |
- |
- |
- |
086 1件: 86 💬 |
412 |
Pemziviptadil (pb1046) injection |
- |
- |
- |
- |
086 1件: 86 💬 |
413 |
Pf-00489791 |
PF-00489791 |
- |
- |
- |
086 1件: 86 💬 |
414 |
Ph-combination therapy |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
415 |
Ph-monotherapy |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
416 |
Pioglitazone |
Pioglitazone |
2件: D00945 D00945, D08378 D08378 💬 |
PPARG 1件: PPARG 💬 |
AMPK signaling pathway 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
002 17件: 2 , 6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
417 |
Placebo |
- |
- |
- |
- |
003 26件: 3 , 5 , 6 , 13, 14, 37, 40, 46, 49, 50, 51, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 💬 |
418 |
Plx-pad |
Placental Mesenchymal Stem Cells |
- |
- |
- |
086 1件: 86 💬 |
419 |
Prednisone |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
420 |
Procedure: b-lines se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
421 |
Procedure: coronary flow reserve se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
422 |
Procedure: diastolic function se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
423 |
Procedure: left ventricular contractile reserve se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
424 |
Procedure: left ventricular outflow tract gradient se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
425 |
Procedure: mitral regurgitation se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
426 |
Procedure: no gas |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
427 |
Procedure: padn |
- |
- |
- |
- |
086 1件: 86 💬 |
428 |
Procedure: pulmonary hemodynamics se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
429 |
Procedure: sham padn |
- |
- |
- |
- |
086 1件: 86 💬 |
430 |
Prostacyclin |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
431 |
Puri-nethol |
- |
- |
- |
- |
086 3件: 86, 96, 97 💬 |
432 |
Q4w gma301 iv injections (1000 mg) |
- |
- |
- |
- |
086 1件: 86 💬 |
433 |
Q4w gma301 iv injections (300 mg) |
- |
- |
- |
- |
086 1件: 86 💬 |
434 |
Q4w gma301 iv injections (600 mg) |
- |
- |
- |
- |
086 1件: 86 💬 |
435 |
Qcc374 |
- |
- |
- |
- |
086 1件: 86 💬 |
436 |
Qcc374 0.015 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
437 |
Qcc374 0.06 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
438 |
Qti571 |
- |
- |
- |
- |
086 1件: 86 💬 |
439 |
Qutenza |
- |
- |
- |
- |
086 1件: 86 💬 |
440 |
Qutenza (8% capsaicin) |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
086 1件: 86 💬 |
441 |
Radiation: pet/ct scan: two pet scans using 1. c-11 hed and 2. n-13 ammonia or rubidium-82 |
Ammonia |
1件: D02916 D02916 💬 |
- |
- |
086 1件: 86 💬 |
442 |
Ralinepag |
Ralinepag |
1件: D10725 D10725 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
443 |
Ranolazine |
Ranolazine |
2件: D05700 D05700, D05701 D05701 💬 |
- |
- |
002 6件: 2 , 58, 86, 96, 113, 114 💬 |
444 |
Rapamycin |
Sirolimus |
1件: D00753 D00753 💬 |
MTOR 1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
002 18件: 2 , 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 96, 157, 158, 256, 278, 279 💬 |
445 |
Rapid dose titration group of subcutaneous treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
446 |
Recombinant human angiotensin-converting enzyme 2 |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
447 |
Recombinant human angiotensin-converting enzyme 2 (ace2), apn01 |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
448 |
Remodulin |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
449 |
Remodulin (treprostinil sodium) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
450 |
Remodulin® (treprostinil) 1 mg/ml solution for infusion |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
451 |
Remodulin® (treprostinil) 10 mg/ml solution for infusion |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
452 |
Remodulin® (treprostinil) 2.5 mg/ml solution for infusion |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
453 |
Remodulin® (treprostinil) 5 mg/ml solution for infusion |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
454 |
Revatio |
- |
- |
- |
- |
085 3件: 85, 86, 113 💬 |
455 |
Revatio 10 mg/ml powder for oral suspension |
- |
- |
- |
- |
086 1件: 86 💬 |
456 |
Revatio 20 mg film coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
457 |
Revatio 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
458 |
Revatio 20 mg filmtabletten |
- |
- |
- |
- |
086 1件: 86 💬 |
459 |
Revatio 20 mg, comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
460 |
Revatio inyectable |
- |
- |
- |
- |
086 1件: 86 💬 |
461 |
Revatio oral |
- |
- |
- |
- |
086 1件: 86 💬 |
462 |
Revatio pos |
- |
- |
- |
- |
086 1件: 86 💬 |
463 |
Revatio tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
464 |
Revatio ® 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
465 |
Revatio® |
- |
- |
- |
- |
086 1件: 86 💬 |
466 |
Riciguat group |
- |
- |
- |
- |
086 1件: 86 💬 |
467 |
Rifampin |
Rifampicin |
1件: D00211 D00211 💬 |
- |
- |
006 5件: 6 , 13, 84, 86, 299 💬 |
468 |
Riociguat |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 6件: 51, 84, 86, 88, 225, 299 💬 |
469 |
Riociguat (adempas, bay63-2521) |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 4件: 51, 86, 88, 299 💬 |
470 |
Riociguat (bay63-2521) |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
471 |
Riociguat granules 0.3% for oral application |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
472 |
Riociguat oral product |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
473 |
Riociguat pill |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
474 |
Ritonavir |
Ritonavir |
1件: D00427 D00427 💬 |
- |
- |
002 3件: 2 , 86, 265 💬 |
475 |
Rituximab |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
011 47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
476 |
Ro 47-0203 |
- |
- |
- |
- |
051 4件: 51, 85, 86, 88 💬 |
477 |
Ro 47-0203 / act-050088 |
- |
- |
- |
- |
086 1件: 86 💬 |
478 |
Ro-47-0203 |
- |
- |
- |
- |
086 1件: 86 💬 |
479 |
Ro-47-0203/029 |
- |
- |
- |
- |
086 1件: 86 💬 |
480 |
Ro47-0203 |
- |
- |
- |
- |
086 1件: 86 💬 |
481 |
Ro47-0203 / act-050088 |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
482 |
Roactemra |
- |
- |
- |
- |
040 9件: 40, 41, 46, 51, 86, 107, 266, 271, 331 💬 |
483 |
Rt234 - vardenafil inhalation powder |
Vardenafil |
3件: D02731 D02731, D03260 D03260, D08668 D08668 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
484 |
Rta 402 |
- |
- |
- |
- |
067 3件: 67, 86, 218 💬 |
485 |
Rubidium |
Rubidium |
- |
- |
- |
084 2件: 84, 86 💬 |
486 |
Rvg 33865 |
- |
- |
- |
- |
086 1件: 86 💬 |
487 |
Rvt-1201 |
- |
- |
- |
- |
086 1件: 86 💬 |
488 |
Salbutamol |
Salbutamol |
1件: D02147 D02147 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
003 9件: 3 , 11, 49, 85, 86, 111, 228, 256, 299 💬 |
489 |
Saline |
- |
- |
- |
- |
006 10件: 6 , 13, 17, 53, 67, 78, 86, 97, 168, 299 💬 |
490 |
Sapropterin |
Sapropterin |
1件: D08505 D08505 💬 |
- |
- |
086 3件: 86, 124, 240 💬 |
491 |
Sapropterin dihydrochloride (6r-bh4) |
Sapropterin |
1件: D08505 D08505 💬 |
- |
- |
086 1件: 86 💬 |
492 |
Saquinavir |
Saquinavir |
2件: D00429 D00429, D01160 D01160 💬 |
- |
- |
086 2件: 86, 265 💬 |
493 |
Saquinavir and ritonavir |
Ritonavir |
3件: D00427 D00427, D00429 D00429, D01160 D01160 💬 |
- |
- |
086 1件: 86 💬 |
494 |
Sauerstoff |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
495 |
Selexipag |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 5件: 51, 70, 84, 86, 88 💬 |
496 |
Selexipag (uptravi) |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
497 |
Selexipag, act-293987 (ns-304) |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
498 |
Selonsertib |
Selonsertib |
1件: D10988 D10988 💬 |
MAP3K5 1件: MAP3K5 💬 |
Alzheimer disease 17件: Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Fluid shear stress and atherosclerosis, Huntington disease, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, Spinocerebellar ataxia, TNF signaling pathway, Thermogenesis, Tight junction |
086 1件: 86 💬 |
499 |
Seralutinib |
- |
- |
- |
- |
086 1件: 86 💬 |
500 |
Serine |
Serine |
1件: D00016 D00016 💬 |
- |
- |
002 3件: 2 , 6 , 86 💬 |
501 |
Sham o2 (medical air) |
Medical air |
- |
- |
- |
086 1件: 86 💬 |
502 |
Sildenaf |
- |
- |
- |
- |
086 1件: 86 💬 |
503 |
Sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 17件: 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
504 |
Sildenafil (as citrate) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
505 |
Sildenafil (revatio) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
506 |
Sildenafil (revatio) 20 mg tid |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
507 |
Sildenafil 20mg |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
508 |
Sildenafil 20mg and bosentan 62.5mg |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
509 |
Sildenafil citrate |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
051 4件: 51, 85, 86, 225 💬 |
510 |
Sildenafil citrate (uk-92,480) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
511 |
Sildenafil filmtabletten |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
512 |
Sildenafil singly or in association with bosentan |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
513 |
Sildenafilo |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
514 |
Simvastatin |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
006 21件: 6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬 |
515 |
Simvastatin 40 mg |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
086 1件: 86 💬 |
516 |
Simvastatin 40 mg tablets |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
086 1件: 86 💬 |
517 |
Sitaxentan |
Sitaxentan |
1件: D07171 D07171 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
518 |
Sitaxentan sodium |
Sitaxentan |
1件: D07171 D07171 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
519 |
Sitaxsentan |
Sitaxentan |
1件: D07171 D07171 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
520 |
Sitaxsentan alone |
Sitaxentan |
1件: D07171 D07171 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
521 |
Sitaxsentan and sildenafil |
Sildenafil |
3件: D02229 D02229, D07171 D07171, D08514 D08514 💬 |
EDNRA 2件: EDNRA, PDE5A 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
522 |
Sitaxsentan sodium |
Sitaxentan |
1件: D07171 D07171 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
523 |
Slow dose titration group of subcutaneous treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
524 |
Sodium nitrite |
Nitrite |
- |
- |
- |
086 2件: 86, 299 💬 |
525 |
Sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 1件: 86 💬 |
526 |
Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth |
Dextrose, unspecified form |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
527 |
Sorafenib |
Sorafenib |
2件: D06272 D06272, D08524 D08524 💬 |
BRAF 8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 |
Acute myeloid leukemia 87件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway |
034 2件: 34, 86 💬 |
528 |
Sotatercept |
Sotatercept |
1件: D09670 D09670 💬 |
ACVR2A 1件: ACVR2A 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway |
086 2件: 86, 284 💬 |
529 |
Spironolactone |
Spironolactone |
1件: D00443 D00443 💬 |
NR3C2 1件: NR3C2 💬 |
Aldosterone-regulated sodium reabsorption 1件: Aldosterone-regulated sodium reabsorption |
058 7件: 58, 67, 86, 113, 210, 218, 225 💬 |
530 |
Spironolactone and conivaptan |
Conivaptan |
3件: D00443 D00443, D01236 D01236, D07748 D07748 💬 |
AVPR1A 3件: AVPR1A, AVPR2, NR3C2 💬 |
Aldosterone-regulated sodium reabsorption 6件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption |
086 1件: 86 💬 |
531 |
Spironolactone captopril carvedilol |
Captopril |
4件: D00251 D00251, D00255 D00255, D00443 D00443, D03415 D03415 💬 |
ACE 7件: ACE, ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, NR3C2 💬 |
AMPK signaling pathway 18件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
532 |
Sti571 |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
533 |
Subcutaneous and intravenous prostacyclin |
Epoprostenol |
2件: D00106 D00106, D01337 D01337 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
534 |
Subcutaneous treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
535 |
Sugar pill |
- |
- |
- |
- |
005 8件: 5 , 6 , 49, 67, 70, 86, 206, 210 💬 |
536 |
Sulfasalazine |
Sulfasalazine |
1件: D00448 D00448 💬 |
- |
- |
046 4件: 46, 86, 94, 271 💬 |
537 |
Sulfate |
Sulfate ion |
- |
- |
- |
002 25件: 2 , 6 , 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 222, 226, 265, 296, 297, 299 💬 |
538 |
Tadalafil |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 7件: 6 , 51, 75, 84, 86, 113, 210 💬 |
539 |
Tadalafil 20 mg film-coated tablets |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
540 |
Tadalafil 40 mg |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
541 |
Tadalafil and ambrisentan upfront combination therapy |
Ambrisentan |
2件: D02008 D02008, D07077 D07077 💬 |
EDNRA 2件: EDNRA, PDE5A 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
542 |
Tadalafil oral suspension |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
543 |
Tadalafil, placebo |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
544 |
Tadalafil- tablet or oral suspension |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
545 |
Tadalafilo |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
546 |
Tamoxifen |
Tamoxifen |
2件: D00966 D00966, D08559 D08559 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
002 4件: 2 , 86, 113, 227 💬 |
547 |
Tasigna |
- |
- |
- |
- |
034 2件: 34, 86 💬 |
548 |
Tasigna® |
- |
- |
- |
- |
086 1件: 86 💬 |
549 |
Tasigna® 150 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
550 |
Tbd |
- |
- |
- |
- |
019 4件: 19, 86, 276, 299 💬 |
551 |
Tegaderm |
- |
- |
- |
- |
086 1件: 86 💬 |
552 |
Terguride |
Terguride |
1件: D01348 D01348 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
051 2件: 51, 86 💬 |
553 |
Terguride 0,5mg tablet |
Terguride |
1件: D01348 D01348 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
086 1件: 86 💬 |
554 |
Terguride 0.5 mg tablet |
Terguride |
1件: D01348 D01348 💬 |
DRD2 2件: DRD2, PRL 💬 |
Alcoholism 12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
086 1件: 86 💬 |
555 |
Tezosentan |
Tezosentan |
- |
- |
- |
086 1件: 86 💬 |
556 |
The pop02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
- |
- |
- |
- |
086 1件: 86 💬 |
557 |
The pops study is collecting pk data on children prescribed the following drugs of interest per standard of care: |
- |
- |
- |
- |
086 1件: 86 💬 |
558 |
Thelin |
- |
- |
- |
- |
086 1件: 86 💬 |
559 |
Threonine |
Threonine |
1件: D00041 D00041 💬 |
- |
- |
086 3件: 86, 96, 97 💬 |
560 |
Thrombin |
Thrombin |
1件: D00090 D00090 💬 |
- |
- |
086 2件: 86, 88 💬 |
561 |
Tocilizumab |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
562 |
Tpn171h |
- |
- |
- |
- |
086 1件: 86 💬 |
563 |
Traclear |
- |
- |
- |
- |
086 1件: 86 💬 |
564 |
Tracleer |
- |
- |
- |
- |
013 8件: 13, 51, 84, 85, 86, 88, 210, 211 💬 |
565 |
Tracleer 62,5 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
566 |
Tracleer 62,5mg 56cpr riv. |
- |
- |
- |
- |
086 1件: 86 💬 |
567 |
Tracleer*125mg 56cpr riv. |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
568 |
Tracleer*56cpr riv 125mg |
- |
- |
- |
- |
051 3件: 51, 86, 88 💬 |
569 |
Tracleer® |
- |
- |
- |
- |
086 1件: 86 💬 |
570 |
Transdihydrolisuride |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
571 |
Tre |
- |
- |
- |
- |
086 1件: 86 💬 |
572 |
Treprosinil diethanolamine |
- |
- |
- |
- |
086 1件: 86 💬 |
573 |
Treprostin |
- |
- |
- |
- |
086 1件: 86 💬 |
574 |
Treprostinil |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 6件: 51, 84, 85, 86, 88, 210 💬 |
575 |
Treprostinil dietanolamina |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
576 |
Treprostinil diethanolamine |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 2件: 51, 86 💬 |
577 |
Treprostinil diolamine |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
578 |
Treprostinil inhalation powder |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
579 |
Treprostinil inhalations |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
580 |
Treprostinil injectable product |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
581 |
Treprostinil sodium |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
051 3件: 51, 86, 88 💬 |
582 |
Treprostinil sodium solution for inhalation |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
583 |
Treprostinil sodium, ut-15 |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
584 |
Treprostinil, ut-15, lrx-15, 15au81, bw a15au, u-62, 840 |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
585 |
Treprostinilo |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
586 |
Trimetazidine |
Trimetazidine |
2件: D01606 D01606, D08642 D08642 💬 |
- |
- |
058 2件: 58, 86 💬 |
587 |
Trk-100stp |
- |
- |
- |
- |
086 1件: 86 💬 |
588 |
Tyrosine |
Tyrosine |
1件: D00022 D00022 💬 |
- |
- |
006 3件: 6 , 86, 111 💬 |
589 |
Tyvaso |
- |
- |
- |
- |
086 1件: 86 💬 |
590 |
Tyvaso inhalation solution |
- |
- |
- |
- |
086 1件: 86 💬 |
591 |
Ubenimex |
Ubenimex |
1件: D00087 D00087 💬 |
ANPEP 1件: ANPEP 💬 |
Glutathione metabolism 4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system |
086 1件: 86 💬 |
592 |
Udenafil |
Udenafil |
1件: D10027 D10027 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 2件: 86, 210 💬 |
593 |
Uk 092480 |
- |
- |
- |
- |
086 1件: 86 💬 |
594 |
Uk-92,480 |
- |
- |
- |
- |
086 1件: 86 💬 |
595 |
Uk-92,480-10 |
- |
- |
- |
- |
086 1件: 86 💬 |
596 |
Uptravi |
- |
- |
- |
- |
084 3件: 84, 86, 88 💬 |
597 |
Ut-15c |
- |
- |
- |
- |
086 1件: 86 💬 |
598 |
Ut-15c (treprostinil diethanolamine) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
599 |
Ut-15c 0.25 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
600 |
Ut-15c 1 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
601 |
Ut-15c 5 mg |
- |
- |
- |
- |
086 1件: 86 💬 |
602 |
Ut-15c lp |
- |
- |
- |
- |
086 1件: 86 💬 |
603 |
Ut-15c sr |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
604 |
Ut-15c sr (treprostinil diethanolamine) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
605 |
Ut-15c-sr |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
606 |
Vardenafil |
Vardenafil |
3件: D02731 D02731, D03260 D03260, D08668 D08668 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
013 3件: 13, 86, 299 💬 |
607 |
Vasomera (pb1046) injection |
- |
- |
- |
- |
086 1件: 86 💬 |
608 |
Veletri |
- |
- |
- |
- |
086 1件: 86 💬 |
609 |
Ventavis |
- |
- |
- |
- |
086 1件: 86 💬 |
610 |
Ventavis (iloprost, bayq6256) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
611 |
Ventavis 10 |
- |
- |
- |
- |
086 1件: 86 💬 |
612 |
Ventavis(iloprost) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
613 |
Viagra |
- |
- |
- |
- |
086 3件: 86, 96, 225 💬 |
614 |
Vip |
- |
- |
- |
- |
049 3件: 49, 51, 86 💬 |
615 |
Volibris |
- |
- |
- |
- |
051 4件: 51, 85, 86, 88 💬 |
616 |
Volibris 10 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
617 |
Volibris 5 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
618 |
Volibris® (ambrisentan) |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
619 |
Volibris™ tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
620 |
Zamicastat |
Zamicastat |
- |
- |
- |
086 1件: 86 💬 |